Drugmakers agree on drug classification, substitutability in União Química-Bayer review
Several pharmaceutical companies have responded to an inquiry from the Brazilian competition authority regarding the proposed acquisition of Bayer's Cicloprimogyna by União Química, largely agreeing on key points regarding product substitutability...To view the full article, register now.
Already a subscriber? Click here to view full article